Foundation Agreement with Biotechnology/Pharmaceutical CompanyFoundation Agreement • October 5th, 2020
Contract Type FiledOctober 5th, 2020We are pleased to inform you that the [Organization] (“[Organization]”) is hereby issuing an award for the Development Program described in Exhibit A and disbursed in accordance with Exhibit B up to the amount indicated above. The awardee, Awardee, shall be responsible for the payment of all of the remaining costs required to complete the Development Program and for costs associated with continuing CRE necessary to further develop and commercialize the Product. Each party’s obligations hereunder will commence and apply upon the execution of this Agreement. The Award is in furtherance of [Organization]’s charitable mission to ______________________. The Award is subject to the following terms, conditions and policies of this Letter Agreement (“Agreement”):
Foundation Agreement with Biotechnology/Pharmaceutical Company Source: Schaner and Lubitz, PLLCFoundation Agreement • July 17th, 2015 • Washington
Contract Type FiledJuly 17th, 2015 JurisdictionWe are pleased to inform you that the [Organization] (“[Organization]”) is hereby issuing an award for the Development Program described in Exhibit A and disbursed in accordance with Exhibit B up to the amount indicated above. The awardee, Awardee, shall be responsible for the payment of all of the remaining costs required to complete the Development Program and for costs associated with continuing CRE necessary to further develop and commercialize the Product. Each party’s obligations hereunder will commence and apply upon the execution of this Agreement. The Award is in furtherance of [Organization]’s charitable mission to ______________________. The Award is subject to the following terms, conditions and policies of this Letter Agreement (“Agreement”):